Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

No Causal Link Found So Far Between J&J's Covid-19 Vaccine and Blood-Clot Cases, Company Researchers Say

04/16/2021 | 11:54am EDT

By Peter Loftus and Jenny Strasburg

Johnson & Johnson said Friday there wasn't enough evidence to establish that the company's Covid-19 vaccine causes the rare blood-clotting condition that prompted U.S. health officials this week to recommend a pause in its use.

The New England Journal of Medicine published online a letter from three J&J employees involved in vaccine development and epidemiology saying, "At this time, evidence is insufficient to establish a causal relationship between these events" and J&J's vaccine.

U.S. health authorities this week recommended a pause in vaccinations using J&J's single-dose vaccine while they investigated six cases of a rare blood clot, combined with low blood-platelet counts, in women who had received the J&J vaccine. One of the women died.

The pause is expected to remain in place at least until a federal vaccine-advisory committee meets April 23 to review the matter.

After U.S. health officials recommended the pause, J&J said it was aware of the events and working with health authorities investigating them. A J&J executive said at a U.S. vaccine-advisory panel meeting this week that causality hadn't been fully established between the clot events and its vaccine, but the company recognized they could be a potential risk with the vaccine.

Health authorities in several countries have restricted use recently of J&J's vaccine, and a shot from AstraZeneca PLC and the University of Oxford that uses a similar technology, after receiving reports of people getting blood clots following their vaccinations.

The authorities said they were acting out of caution, while they probe the rare adverse events further.

It isn't clear whether the two vaccines caused the rare cases of blood clots and low counts of platelets, which play a role in clotting.

Researchers in Germany and Norway said last month they found the AstraZeneca-Oxford vaccine could trigger an autoimmune reaction causing blood clots. European health authorities said they had found possible links between the events and the AstraZeneca-Oxford vaccine, though the shot's benefits exceed its potential risks.

AstraZeneca has said it agreed with the assessment of European and other health authorities that its vaccine's benefits outweighed its risks. The company hasn't said whether it agreed there was evidence of a link between its vaccine and severe blood clotting.

"The safety of all patients is paramount and we are working with regulators to understand the individual cases, epidemiology and possible mechanisms that could explain these extremely rare events," AstraZeneca said through a spokesman.

The J&J researchers wrote to the medical journal in response to a case report the journal published earlier this week, describing the clotting condition in a 48-year-old woman in Nebraska, which developed two weeks after she received the J&J vaccine. She was critically ill at the time of the case report.

The doctors who wrote the case report about the woman in Nebraska suggested that the rare clotting events, coupled with low platelets, could be related to the type of vaccine technology in the J&J vaccine, known as viral vector.

They noted that similar cases had been seen in recipients of the AstraZeneca's vaccine, which is also a viral-vector vaccine.

The J&J researchers said in their letter the six cases were among more than 7.2 million people vaccinated with J&J's shot. The researchers also said there were differences between the designs of J&J's vaccine and the AstraZeneca-Oxford shot, and therefore the vaccines may have different biologic effects.

"We continue to work closely with experts and regulators to assess the data, and we support the open communication of this information to health care professionals and the public," the J&J researchers said.

The letter was written by Jerald Sadoff, senior adviser with J&J's vaccine division; Kourtney Davis, senior director and head of global epidemiology at J&J's pharmaceutical division; and Macaya Douoguih, head of clinical development and medical affairs with J&J's pharmaceutical unit.

Write to Peter Loftus at peter.loftus@wsj.com and Jenny Strasburg at jenny.strasburg@wsj.com

(END) Dow Jones Newswires

04-16-21 1354ET

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.44% 7930 Delayed Quote.7.80%
DJ INDUSTRIAL -0.20% 34256.48 Delayed Quote.12.34%
JOHNSON & JOHNSON 0.14% 170.72 Delayed Quote.8.27%
All news about JOHNSON & JOHNSON
09:06aJOHNSON & JOHNSONá : NAFDAC Approves 'Johnson and Johnson' Covid-19 Vaccine
AQ
08:32aJOHNSON & JOHNSONá : Arrowhead Earns $10 Million Option Exercise Fee for Joint P..
MT
02:59aMARKET CHATTER : Johnson & Johnson Halves COVID-19 Deliveries to EU This Week as..
MT
05/17EXPLAINER : How Ohio's Vax-a-Million lottery will work
AQ
05/17Biden Commits to Exporting More Covid-19 Vaccines -- 5th Update
DJ
05/17Biden boosting world vaccine sharing commitment to 80M doses
AQ
05/17Biden Commits to Exporting More Covid-19 Vaccines -- 4th Update
DJ
05/17Biden Commits to Exporting More Covid-19 Vaccines -- 3rd Update
DJ
05/17JOHNSON & JOHNSONá : South Africa's Tutu gets jab to help start inoculation driv..
AQ
05/17Biden to Commit to Exporting Covid-19 Vaccines by End of June -- 2nd Update
DJ
More news
Financials (USD)
Sales 2021 92 844 M - -
Net income 2021 22 227 M - -
Net Debt 2021 1 328 M - -
P/E ratio 2021 20,5x
Yield 2021 2,45%
Capitalization 449 B 449 B -
EV / Sales 2021 4,85x
EV / Sales 2022 4,54x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 183,67 $
Last Close Price 170,39 $
Spread / Highest target 19,7%
Spread / Average Target 7,79%
Spread / Lowest Target -7,27%
EPS Revisions
Managers and Directors
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON8.27%448 704
ROCHE HOLDING AG-1.39%292 944
PFIZER, INC.8.54%224 524
ABBVIE INC.8.75%206 454
MERCK & CO., INC.-3.15%202 236
NOVARTIS AG-4.18%199 700